YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies

Sponsor
West China Hospital
Study ID
NCT07763301
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • YMN-136 vaccine — BIOLOGICAL
    The YMN-136 vaccine will be administered according to the dose level assigned to each patient. Approximately every 3 weeks, the vaccine will be administered via intramuscular injection into the single upper arm, with 4 doses for prime immunization.

Study Details

This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with advanced hepatobiliary and pancreatic malignancies.

Key Dates

First listed
Aug 13, 2026
Start date
Aug 1, 2026
Status verified
Aug 2026
Primary completion
Feb 29, 2028
Completion
May 31, 2028

Study Design

Enrollment
9 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: YMN-136 vaccine treatment

Primary Outcome Measure

Incidence of Treatment-Related Adverse Events [ Time Frame: Approximately 24 months ]

Central Contacts

Find similar trials

Nationwide
Liver cancer trialsPancreatic cancer trialsOncology trialsGI oncology trialsHepatology trials

Related Studies